| Detected | Trial | Change |
|---|---|---|
| 2026-08-08 | NCT07242352 Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine… |
Sponsor changed: West German Study Group -> Women's Cancer Study Group GmbH |
| 2026-08-08 | NCT07242352 Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine… |
Trial sites expanded: 1 -> 33 locations |
| 2026-08-06 | NCT05792150 PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS |
Sponsor changed: West German Study Group -> Women's Cancer Study Group GmbH |
| 2026-08-06 | NCT07178730 NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… |
Sponsor changed: West German Study Group -> Women's Cancer Study Group GmbH |
| 2026-08-06 | NCT07281833 Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of… |
Sponsor changed: West German Study Group -> Women's Cancer Study Group GmbH |
| 2026-08-06 | NCT07281833 Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of… |
Trial sites expanded: 7 -> 16 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07281833 | Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of… | Breast Cancer | Recruiting |
| NCT07242352 | Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine… | Breast Cancer | Recruiting |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in… | Breast Cancer | Not Yet Recruiting |
| Not specified | |||
| NCT05792150 | PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS | Female Breast Cancer | Recruiting |